Convenience And Preferability Among Patients with Sickle Cell Anemia on Iron Cheloter
DOI:
https://doi.org/10.59675/U323Keywords:
Iron-chelation therapy, iron-excess, sickle-cell illnessAbstract
Background: SCD is a chronic hemolytic disease that is significant and has a broad spectrum of complications. The value of blood transfusion in SCD is becoming increasingly evident. If left untreated, the resulting iron excess can be life-threatening. Parenteral infusions are necessary for chelation therapy with deferoxamine, which can have a detrimental effect on drug adherence and quality of life.
Methods: Deferoxamine (20-50 mg\kg\day) or oral deferasirox (20-40 mg\kg\day) was administered to 97 patients in a 2:1 randomized fashion. A total of 60 patients have received this medication previously.
Results: At the end of each interval of questioning, a significantly greater number of people who passed the time up and took medication were either (satisfied\ delighted) with deferasirox or identified the treatment as {preferable\very preferable} compared to deferoxamine (p = 0,001). Deferasirox resulted in fewer hours lost from daily activities than deferoxamine in those patients. At the conclusion of the investigation, most patients expressed their willingness to continue their oral therapy (84 vs 11%).
Conclusions: Therefore, patients with SCD are more satisfied with deferasirox, as it exerts a lesser impact on daily activities than deferoxamine. Enhanced quality of life is associated with a high level of satisfaction. The improved treatment outcome is associated with high oral chelation adherence.
Downloads
References
Adams RJ, McKie V, Abboud M. Prevention of a first stroke in children with sickle cell disease and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998; 339:5–11.
Miller ST, Wright E, Adams RJ. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle cell disease. J Pediatr. 2001; 139:785–789.
Wang WC, Morales KH, Scher CD. Effect of long-term transfusion on growth in children with sickle cell disease. J Pediatr. 2005; 147:244–247.
Styles LA, Vichinsky E. Effect of long-term transfusion regimen on sickle cell disease–related illnesses. J Pediatr. 1994; 125:909–911.
Wanka SO, Telen MJ. Transfusion management in sickle cell disease. Hematol Oncol Clin North Am. 2005; 19:803–826.
Brittenham GM, Griffith PM, Nienhuis AW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331:567–573.
Kwiatkowski JL, Cohen AR. Iron chelation therapy in sickle cell disease and other transfusion-dependent anemias. Hematol Oncol Clin North Am. 2004; 18:1355–1377.
Claster S, Vichinsky EP. Managing sickle cell disease. BMJ. 2003; 326:1151–1154.
Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol. 2001; 38:5–11.
Vichinsky E. Consensus document for transfusion-related iron overload. Semin Hematol. 2001; 38:2–4.
Vichinsky EF. Current issues with blood transfusions in sickle cell disease. Semin Hematol. 2001; 38:14–22.
Gabutti V, Piga A. Results of long-term iron chelating therapy. Acta Haematol. 1996; 95:26–36.
Reulla P. Transfusion reactions in thalassemia: a survey from the Cookycare program. Haematologica. 1990; 75:122–127.
Ward A, Caro JJ. An international survey of thalassemia major with lifelong deferoxamine therapy. BMC Clin Pharmacol. 2002; 2:3.
Gabutti V, Borgna-Pignatti C. Clinical manifestations and therapy of transfusional haemosiderosis. Baillieres Clin Haematol. 1994; 7:919–940.
Cohen AR, Martin MB. Iron chelation therapy in sickle cell disease. Semin Hematol. 2001; 38:69–72.
Silliman CC, Peterson VM, Mellman DL. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis. Medicine (Baltimore). 1993; 72:48–54.
Arboretti R, Tognoni G. Pharmacovigilance and quality of care of thalassemic patients: a large-scale epidemiological survey. Eur J Clin Pharmacol. 2001; 56:915–922.
Sekeres MA, Stone RM, Zahnieh D. Decision-making and quality of life in older adults with acute myeloid leukemia. Leukemia. 2004; 18:809–815.
Cappellini MD, Magnano C, Alberti D. Once-daily oral chelator in patients with thalassemia. Blood. 2006; 107:3455–3462.
Vichinsky E, Hassel K, Alberti D. A randomized comparison of deferasirox versus deferoxamine in iron overload in sickle cell disease. Br J Haematol. 2007; 136:501–508.
Cappellini MD, Porter J, Jeng M, Baladi JF. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta thalassemia. Clin Ther. 2007; 29:909–917.
Poole JE, Cohn RJ, Roode H. Beta thalassemia—the Johannesburg experience. S Afr Med J. 1989; 75:367–370.
Mantovani LG, Cappellini MD; Study Group. Quality of life and satisfaction with iron chelation in beta-thalassemia. Blood. 2006; 108:3344.
Rofail D, Viala M. Satisfaction with chelation in patients with thalassemia and myelodysplastic syndromes. Haematologica. 2006; 91:1294.
Wood J, Paley C, Kang B. Exjade reduces cardiac iron burden in thalassemic patients: an MRI study. Blood. 2007; 110:2781.
Pippard MJ, Callender ST, Warner CT. Deferoxamine excretion in iron-overloaded man. Blood. 1982; 60:288–294.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Academic International Journal of Medical Update
This work is licensed under a Creative Commons Attribution 4.0 International License.
